BOLERO-3: Adding Everolimus Improves PFS in HER2+ Breast Cancer Cancer Network The addition of everolimus (Novartis) to combination trastuzumab/vinorelbine led to a significant improvement in progression-free survival (PFS) compared with placebo in advanced and metastatic HER2-positive breast cancer, according to results ... |
